Published on 09 Apr 2013
Sign up for email alerts to receive notifications of new articles published in Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine
Chronic obstructive pulmonary disease (COPD) is the fourth leading cause of death worldwide and is projected to be the third by 2020. COPD is characterized by chronic airflow limitation caused by airway inflammation and parenchymal destruction that is usually progressive. Inhaled bronchodilators continue to be the mainstay of the current management of COPD. Safety and efficacy data of the recently approved medications including aclidinium, glycopyrronium, roflumilast, and indacaterol are reviewed here.
PDF (538.25 KB PDF FORMAT)
RIS citation (ENDNOTE, REFERENCE MANAGER, PROCITE, REFWORKS)
BibTex citation (BIBDESK, LATEX)
I would like to say that this is the most author-friendly editing process I have experienced in over 50 publications. The publishing process of this journal was a most pleasant and productive experience. I was particularly impressed with the regular updates of the progress of my submission. My experience with Libertas Academica was excellent.